Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions
Ewing SarcomaOsteosarcoma
Interventions
DRUG

Cabozantinib

Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.

Trial Locations (4)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

NOT_YET_RECRUITING

University of Pennsylvania, Philadelphia

80045

RECRUITING

Children's Hospital Colorado, Aurora

94143

NOT_YET_RECRUITING

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Children's Hospital Colorado

OTHER

collaborator

Alex's Lemonade Stand Foundation

INDUSTRY

collaborator

Exelixis

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER

NCT06156410 - Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma | Biotech Hunter | Biotech Hunter